| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5654994 | Clinical Immunology | 2016 | 16 Pages |
Abstract
The folic acid analogue methotrexate is used as an anti-neoplastic agent and treatment for inflammatory disorders including psoriasis, dermatomyositis, lupus erythematous, sarcoidosis, and systemic sclerosis. Despite the introduction of newer biologic agents, methotrexate remains a first-line systemic therapy for many patients with disorders of chronic inflammation. Here we briefly describe the current clinical evidence for methotrexate use in psoriatic disease, our current understanding of methotrexate's anti-inflammatory properties, and the future role of methotrexate in the treatment of immune mediated disorders.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Jacqueline E. Greb, Ari M. Goldminz, Alice B. Gottlieb,